

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM674973

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
JPMORGAN CHASE BANK, N.A., as Administrative Agent		09/08/2021	National Banking Association: UNITED STATES
RECEIVING PARTY DATA			
Name:	BELCHER PHARMACEUTICALS, LLC		
Street Address:	6911 Bryan Dairy Road		
City:	Largo		
State/Country:	FLORIDA		
Postal Code:	33777		
Entity Type:	Limited Liability Company: FLORIDA		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Serial Number:	87284561	ADRENATAB	
Registration Number:	5734174	ABLYSINOL	
Registration Number:	4990294	TRUPROFEN FLAVORED TAB	
Registration Number:	4985278	VETPROFEN FLAVORED TAB	
Registration Number:	3509803	VETPROFEN	
CORRESPONDENCE DATA			
Fax Number:	7043311159		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	7043311000		
Email:	PTO_TMconfirmation@mvalaw.com, maryelizabethzaldivar@mvalaw.com		
Correspondent Name:	Moore & Van Allen PLLC		
Address Line 1:	100 North Tryon Street		
Address Line 2:	Suite 4700, ATTN: IP DEPARTMENT		
Address Line 4:	Charlotte, NORTH CAROLINA 28202		
ATTORNEY DOCKET NUMBER:	026618.001357		
NAME OF SUBMITTER:	John Slaughter		
SIGNATURE:	/john slaughter/		

OP \$140.00 87284561

DATE SIGNED:	09/16/2021
---------------------	------------

Total Attachments: 4

source=RSI-IPC - JPMorgan Chase Bank, N.A., as Administrative Agent to Belcher Pharmaceuticals, LLC#page1.tif

source=RSI-IPC - JPMorgan Chase Bank, N.A., as Administrative Agent to Belcher Pharmaceuticals, LLC#page2.tif

source=RSI-IPC - JPMorgan Chase Bank, N.A., as Administrative Agent to Belcher Pharmaceuticals, LLC#page3.tif

source=RSI-IPC - JPMorgan Chase Bank, N.A., as Administrative Agent to Belcher Pharmaceuticals, LLC#page4.tif

**RELEASE OF SECURITY INTEREST
IN INTELLECTUAL PROPERTY COLLATERAL**

This **RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL** (this "Release"), dated as of September 8, 2021, is made by **JPMORGAN CHASE BANK, N.A.**, as **Administrative Agent** (the "Administrative Agent"), under the **Credit Agreement** referred to below (terms used in this Release and not herein defined shall have the meanings set forth in the **Credit Agreement** or the **IP Security Agreements** referred to below), in favor of Belcher Pharmaceuticals, LLC, a Florida limited liability company ("Grantor").

WHEREAS, in connection with that certain **Credit Agreement** (as amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), dated as of September 10, 2020, by and among the Grantor, the Lenders party thereto and **Administrative Agent**, the Lenders agreed to make loans and extend other financial accommodations to or for the benefit of the Grantor;

WHEREAS, the Grantor entered into that certain **Pledge and Security Agreement** (as amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement"), dated as of September 10, 2020 in favor of the **Administrative Agent**;

WHEREAS, in connection with the **Credit Agreement** and the **Security Agreement** and pursuant to those certain agreements described on Annex I attached hereto (the "IP Security Agreements"), the Grantor pledged and granted to the **Administrative Agent**, on behalf of the **Secured Parties**, a security interest in all of the Grantor's right ,title and interest in and to the **Patents and Trademarks**, including those listed on Annex I attached hereto (collectively, the "IP Collateral"); and

WHEREAS, the **IP Security Agreements** were recorded in the **United States Patent and Trademark Office**, on the dates and on the reels/frames set forth on Annex I attached hereto.

NOW THEREFORE, in consideration of the material covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the **Administrative Agent**, on behalf of the **Secured Parties**, hereby **RELEASES**, terminates and discharges, without representation, recourse or warranty whatsoever, all of its rights in, to and under the **IP Collateral**, including its security interest in all of the Grantor's right, title and interest in and to the **IP Collateral**, whether granted pursuant to the **Security Agreement**, the **IP Security Agreements** or any other agreement or document delivered in connection with the **Credit Agreement**, and the **Administrative Agent** hereby reassigns any and all such right, title and interest (if any) that the **Administrative Agent** may have in, to and under the **IP Collateral** to the Grantor.

The **Administrative Agent** agrees, at the Grantor's sole expense, to cooperate with the Grantor and to provide the Grantor with the information and additional authorization reasonably required or desirable to effect the release of the **Administrative Agent's security interest in the released collateral** described herein.

This Release and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York.

[Signature Page Follows]

IN WITNESS WHEREOF, the Administrative Agent, on behalf of the Secured Parties, has executed this Release as of the date first above written.

JPMORGAN CHASE BANK, N.A.,
as Administrative Agent

By: *L. Zvaleuskas*
Name: *Leon Zvaleuskas*
Title: *Authorized Officer*

Supplemental Confirmatory Grant of Security Interest in United States Trademarks dated as of September 10, 2020, by Belcher Pharmaceuticals, LLC in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on September 10, 2020 at Reel/Frame No. 7048/0392.

Trademarks and Trademark Applications

Trademark	App. No. App. Date	Reg. No. Reg. Date	Owner
ADRENATAB	87284561 12/29/2016		Belcher Pharmaceuticals, LLC
ABLYSINOL	86703980 7/24/2015	5734174 4/23/2019	Belcher Pharmaceuticals, LLC
TRUPROFEN FLAVORED TAB	86709488 7/30/2015	4990294 6/28/2016	Belcher Pharmaceuticals, LLC
VETPROFEN FLAVORED TAB	86707946 7/29/2015	4985278 6/21/2016	Belcher Pharmaceuticals, LLC
VETPROFEN	77328434 11/13/2007	3509803 9/30/2008	Belcher Pharmaceuticals, LLC

Supplemental Confirmatory Grant of Security Interest in United States Patents dated as of September 10, 2020, by Belcher Pharmaceuticals, LLC in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on September 10, 2020 at Reel/Frame No. 053731/0843.

Patents and Patent Applications

Title	App. No. App. Date	Reg. No. Reg. Date	Owner
[Solid oral formulations having an iron sugar overcoat]	15/812,671 11-14-2017	10080722 09-25-2018	Belcher Pharmaceuticals, LLC
More potent and less toxic formulations of epinephrine and methods of medical use	15/616,157 06-07-2017	10039728 08-07-2018	Belcher Pharmaceuticals, LLC
More potent and less toxic formulations of epinephrine and methods of medical use	15/596,440 05-16-2017	10004700 06-26-2018	Belcher Pharmaceuticals, LLC
Solid oral formulations having an iron sugar overcoat	14/753,776 06-29-2015	9849091 12-26-2017	Belcher Pharmaceuticals, LLC
More potent and less toxic formulations of epinephrine and methods of medical use	14/460,845 08-15-2014	9283197 03-15-2016	Belcher Pharmaceuticals, LLC
Methods of non-gastrointestinal endoscopic procedures using L-hyoscyamine oral formulations	14/611,635 02-02-2015	9155731 10-13-2015	Belcher Pharmaceuticals, LLC
More palatable, bioequivalent pharmaceutical composition of carprofen	14/329,970 07-13-2014	9155704 10-13-2015	Belcher Pharmaceuticals, LLC
Veterinary composition and method	14/159,840 01-21-2014	9034912 05-19-2015	Belcher Pharmaceuticals, LLC
Methods of non-gastrointestinal endoscopic procedures using L-hyoscyamine oral formulations	13/965,819 08-13-2013	8946258 02-03-2015	Belcher Pharmaceuticals, LLC
Veterinary composition and method	13/427,966 03-23-2012	8653128 02-18-2014	Belcher Pharmaceuticals, LLC
More potent and less toxic formulations of epinephrine and methods of medical use	15/616,157 06-07-2017	10039728 08-07-2018	Belcher Pharmaceuticals, LLC
More palatable, bioequivalent pharmaceutical composition of carprofen	14/329,970 07-13-2014	9155704 10-13-2015	Belcher Pharmaceuticals, LLC
Methods of non-gastrointestinal endoscopic procedures using L-hyoscyamine oral formulations	14/611,635 02-02-2015	9155731 10-13-2015	Belcher Pharmaceuticals, LLC
Methods of non-gastrointestinal endoscopic procedures using L-hyoscyamine oral formulations	13/965,819 08-13-2013	8946258 02-03-2015	Belcher Pharmaceuticals, LLC
MORE POTENT AND LESS TOXIC FORMULATIONS OF EPINEPHRINE AND METHODS OF MEDICAL USE	15/991,501 05-29-2018	[pending]	Belcher Pharmaceuticals, LLC
Veterinary composition and method	13/427,966 03-23-2012	8653128 02-18-2014	Belcher Pharmaceuticals, LLC
More potent and less toxic formulations of epinephrine and methods of medical use	15/596,440 05-16-2017	10004700 06-26-2018	Belcher Pharmaceuticals, LLC
Veterinary composition and method	14/159,840 01-21-2014	9034912 05-19-2015	Belcher Pharmaceuticals, LLC
More potent and less toxic formulations of epinephrine and methods of medical use	14/460,845 08-15-2014	9283197 03-15-2016	Belcher Pharmaceuticals, LLC